Cerus (NASDAQ:CERS – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Cerus to similar companies based on the strength of its profitability, institutional ownership, valuation, earnings, risk, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current recommendations for Cerus and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cerus | 1 | 1 | 3 | 0 | 2.40 |
| Cerus Competitors | 4330 | 10559 | 18358 | 840 | 2.46 |
Cerus presently has a consensus target price of $5.25, indicating a potential upside of 183.17%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.79%. Given Cerus’ higher possible upside, equities research analysts plainly believe Cerus is more favorable than its competitors.
Earnings and Valuation
This table compares Cerus and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cerus | $226.57 million | -$15.63 million | -61.80 |
| Cerus Competitors | $1.90 billion | $136.32 million | 5.94 |
Cerus’ competitors have higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
78.4% of Cerus shares are owned by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Cerus and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cerus | -3.23% | -10.44% | -3.42% |
| Cerus Competitors | -191.42% | -197.86% | -21.83% |
Risk and Volatility
Cerus has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Cerus’ competitors have a beta of 2.57, indicating that their average stock price is 157% more volatile than the S&P 500.
Summary
Cerus competitors beat Cerus on 7 of the 13 factors compared.
Cerus Company Profile
Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components. INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
